Knowledge and cardiovascular disease risk among patients are taking cardiovascular related medications;Conocimiento y riesgo cardiovascular en pacientes en tratamiento con medicamentos cardiovasculares

Ars Pharmaceutica

Volumn 46, Issue 3, 2005, Pages 279-300

  Amariles, P ^a,b   Baena, M I ^b   Faus, M J ^b   Machuca, M ^c   Tudela, J ^d   Barris, D ^d   Sevilla, J ^e   Roman Alvarado J ^f   Machuca, M P ^f   Cansino, J ^c,f  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSITY OF SEVILLE   (Spain)

^d Farmacéutico Comunitario Málaga   (Spain)

^e Farmacéutico Comunitario Granada   (Spain)

^f Farmacéutico Comunitario Sevilla   (Spain)

Author keywords

Cardiovascular disease risk; Community pharmacy; Knowledge; Questionnaire

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHI SQUARE TEST; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; EDUCATION; EXERCISE; FEMALE; HEALTH SURVEY; HUMAN; HYPERTENSION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCEPTION; PHARMACEUTICAL CARE; PHARMACY; RISK ASSESSMENT; RISK FACTOR; SMOKING; SPAIN; STATISTICAL ANALYSIS; STUDENT T TEST;

EID: 27744442742     PISSN: 00042927     EISSN: 00042927     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Instituto Nacional de Estadística de España. España en cifras 2003-2004. Salud. Defunciones según las causas de muerte más significativas. Disponible en www.ine.es/especif/especifes/ especif0304.htm
2. Junta de Andalucía, Consejería de Salud. Riesgo Vascular: Proceso Asistencial Integrado. Sevilla, Consejería de Salud, 2003. 241 p.
3. Gavin JR 3rd, Peterson K, Warren-Boulton E; National Diabetes Education Program. Reducing cardiovascular disease risk in patients with type 2 diabetes: a message from the National Diabetes Education Program. Am Fam Physician 2003; 68:1569-1574.
4. Brotons C, Royo-Bordonada MA, Álvarez-Sala L, et al. Comité Español Interdisciplinario para la Prevención Cardiovascular (CEIPC). Adaptación Española de la Guía Europea de Prevención Cardiovascular. Clin Invest Arteriosc 2005; 17:19-33.
5. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527-1535.
6. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326:1427-1431.
7. Pini R, Cavallini MC, Bencini F, et al. Cardiac and Vascular Remodeling in Older Adults With Borderline Isolated Systolic Hypertension: The ICARe Dicomano Study. Hypertension 2001; 38:1372-1376.
8. LaRosa JC, He J, Vupputuri S. Effects of statins on risk of coronary disease: a meta-analysis of randomized control trials. JAMA 1999; 282:2340-2346.
9. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: metaanalysis of randomized trials. BMJ 2000; 321:983-986.
10. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363:757-767.
11. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic hearth disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326:1423-1427.
12. Huang ES, Meigs JB, Singer DE: The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 2002; 111:633-642.
13. Wilson K, Gibson N, Willian A, Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000; 160:939-944.
14. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003; 290:86-97.
15. Ministerio de Sanidad y Consumo - España. Instituto Información S.N.S. Encuesta Nacional de Salud 2001: Primera oleada Noviembre 2003. Disponible en: www.msc.es/Diseno/informacionProfesional/ profesional_sistemas_informacion.htm.
16. Grupo de Prevención Cardiovascular del Programa de Actividades Preventivas y Promoción de la Salud (PAPPS) de la Sociedad Española de Medicina de Familia y Comunitaria (semFYC). Guía de Prevención Cardiovascular. 2 ed. Barcelona: Semfyc, 2003; 76 p. Disponible en:http://www.papps.org/publicaciones/cardio.pdf.
17. Amariles P, Machuca M, Jiménez-Faus A, et al. Riesgo cardiovascular: componentes, valoración e intervenciones preventivas. Ars Pharmaceutica 2004; 45:187-210.
18. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J. Executive summary European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24:1601-1610.
19. Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987-1003.
20. Gerber J, Parra D, Beckey NP, Korman L. Optimizing Drug Therapy in Patients with Cardiovascular Disease: The impact of Pharmacist-Managed Pharmacotherapy Clinics in Primary Care Setting. Pharmacotherapy 2002; 22:738-747.
21. Simpson DR, Dixon BG, Bolli P. Effectiveness of multidisciplinary patient counselling in reducing cardiovascular disease risk factors through nonpharmacological intervention: results from Healthy Heart Program. Can J Cardiol 2004; 20:177-186.
22. Atthobari J, Monster TBM, de Jong PE, de Jong-van den Berg LTW. The effect of hypertension and hypercholesterolemia screening with subsequent intervention letter on the use of blood pressure and lipid lowering drugs. Br J Clin Pharmacol 2003; 57:328-336.
23. Hilleman DE, Monaghan MS, Ashby CL, Mashni JE, Woolley K, Amato CM. Physician-Prompting Statin Therapy Intervention Improves Outcomes in Patients with Coronary Heart Disease. Pharmacotherapy 2001; 21:1415-1421.
24. Gluckman TyJ, Baranowski B, Ashen MD. A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction. Arc Intern Med 2004; 264:2490-1500.
25. Frijling BD, Lobo CM, Keus IM, Jenks KM, Akkermans RP, et al. Perceptions of cardiovascular risk among patients with hypertension or diabetes. Patient Educa Couns 2004; 52:47-53.
26. Lafarga Giribets MA, Monfort Cabane M, Sanchez Pellicer R, Batlle Farran F. Relación entre el desconocimiento del propio peso y el riesgo cardiovascular en atención primaria. Aten Primaria. 2003; 32:466-470.
27. Celentano A, Panico S, Palmieri V, Guillaro B, et al. Citizens and family doctors facing awareness and management of traditional cardiovascular risk factors. Nutr Metab Cardiovasc Dis 2003; 13:211-217.
28. Puras A, Sanchís C, Artigao LM,División JA. Prevalence, awareness and control of hypertension. Eur J Epid 1998;14:31-36.
29. Banegas JR, Rodriguez-Artalejo F, Cruz JJ, Guallar P, Rey J. Blood pressure in Spain: distribution, awareness, control, and benefits of a reduction in average pressure. Hypertension 1998; 32:998-1002..
30. McGrae-Mcdermott M, Luna-Mandapat A, Moates A, Albay M, Chiou E, Celic L, et al. Knowledge and Attitudes Regarding Cardiovascular Disease Risk and Prevention in Patients With Coronary or Peripheral Arterial Disease. Arch Inter Med 2003; 163:2157-2162.